Co-Founder/CSO
AT
AtG Therapeutics
AtG develops novel small molecule drug candidates and associated biomarkers to target cancer metabolic adaptation. Their approach focuses on overcoming tumor vulnerabilities in both treatment-naïve and resistant cancer patients. The company aims to advance its therapeutic portfolio into clinical trials to improve outcomes for advanced cancer patients.
- Biotechnology
Updated 2 months ago
Funding
Raised to date
€556KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Est. $606Kacross 1 round
BGIWA€556K · Seed
Announced Jul 2022
Disclosed cumulative: $606K
RoundDateAmountValuationInvestors
Founders
Product
Features
- AtG develops novel small molecule drug candidates and associated biomarkers to target cancer metabolic adaptation. Their approach focuses on overcoming tumor vulnerabilities in both treatment-naïve and resistant cancer patients. The company aims to advance its therapeutic portfolio into clinical trials to improve outcomes for advanced cancer patients.